Euthymics Bioscience (Cambridge, MA) a clinical-stage small molecule company focused on CNS disorders and depression, closed a $24M Series A financing. Participants include Novartis Venture Fund, Venture Investors, H&Q Capital Management and GBS Venture Partners.